Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment

Reuters

2025/06/02

Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment

Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540767764"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540767764\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540767764?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540767764","market":"us","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-02 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL23xm4s:1","article_id":"2540767764","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540767764","pubTimestamp":1748863833,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference  therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7  expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule  platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","ARWR":"Arrowhead Research Corporation"},"translate_title":"Arrowhead Pharmaceuticals启动ARO-ALK7治疗肥胖的1/2a期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":0.9},"content_text":"Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n    \n\n        Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}